IthaID: 3339
Names and Sequences
Functionality: | Disease modifying mutation | Pathogenicity: | N/A |
---|---|---|---|
Common Name: | rs2146323 | HGVS Name: | NG_008732.1:g.12143C>A |
Context nucleotide sequence:
GGACTTACGTTAGATTTTGGAAGGA [A/C] TTGCCTGATTCGGAAGCTCCAAAGA (Strand: +)
Also known as:
Comments: SNP (C>A) strongly associated with high HbF levels in β-thalassaemia patients and hence, a milder clinical phenotype of the disease. The A allele also associated with hydroxyurea treatment efficacy (high HbF levels) in SCD/β-thalassaemia patients.
We follow the HGVS sequence variant nomenclature and IUPAC standards.
External Links
Phenotype
Allele Phenotype (Cis): | N/A |
---|---|
Allele Phenotype (Trans): | N/A |
Associated Phenotypes: |
Hb F levels [HP:0011904] [OMIM:141749] Hb F response to hydroxyurea |
Location
Chromosome: | 6 |
---|---|
Locus: | NG_008732.1 |
Locus Location: | 12143 |
Size: | 1 bp |
Located at: | VEGFA |
Specific Location: | Intron 2 |
Other details
Type of Mutation: | Point-Mutation(Substitution) |
---|---|
Effect on Gene/Protein Function: | N/A |
Ethnic Origin: | Greek |
Molecular mechanism: | N/A |
Inheritance: | Quantitative trait |
DNA Sequence Determined: | Yes |
In silico pathogenicity prediction
Note:
The impact thresholds provided in this section are based on the analyses performed in Tamana et.al. For any given tool, the impact thresholds defined for the set of variants with the same effect on function as the variant examined, are preferred over those defined for the full dataset.
Sequence Viewer
Note: The NCBI Sequence Viewer is not installed on the ITHANET servers but it is embedded in this page from the NCBI.
Therefore, IthaGenes has no responsibility over any temporary unavailability of the service.
In such a case, please Refresh the page or retry at a later stage.
Otherwise, use this external link.
Publications / Origin
- Chondrou V, Kolovos P, Sgourou A, Kourakli A, Pavlidaki A, Kastrinou V, John A, Symeonidis A, Ali BR, Papachatzopoulou A, Katsila T, Patrinos GP, Whole transcriptome analysis of human erythropoietic cells during ontogenesis suggests a role of VEGFA gene as modulator of fetal hemoglobin and pharmacogenomic biomarker of treatment response to hydroxyurea in β-type hemoglobinopathy patients., Hum. Genomics , 11(1), 24, 2017 PubMed
Created on 2018-06-25 17:13:27,
Last reviewed on 2019-05-20 16:10:28 (Show full history)
A/A | Date | Curator(s) | Comments |
---|---|---|---|
1 | 2018-06-25 17:13:27 | The IthaGenes Curation Team | Created |
2 | 2019-05-20 16:10:28 | The IthaGenes Curation Team | Reviewed. Mutation comment updated. |
Disclaimer: The information on this website is provided as an information resource only
and must not to be used as a substitute for professional diagnosis and treatment.
The ITHANET Portal and IthaGenes are not responsible or liable for any advice, course of treatment,
diagnosis or any other information, services or products that an individual obtains through this website.
IthaGenes was last updated on 2024-11-20 13:24:07